ABC6310082 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Cencora, Inc. 3.95% 13-FEB-2029 bond, identified as ABC6310082. It outlines key facts about the issuer, bond classification, credit risk assessment, and agents involved. The profile also extensively details interest payment information, including the coupon rate, frequency, upcoming payout schedule, and bond redemption details.
Cencora (COR) Adds Robert E. Sanchez To Its Board, Is The Stock Still Cheap?
Cencora (COR) has appointed Robert E. Sanchez to its board as an independent director, bringing his experience from Ryder System and Texas Instruments. The stock has seen mixed performance recently, with a 6.62% drop over 30 days but a 3.52% gain over 90 days, and significant long-term growth. Despite recent softening, the company is considered 16% undervalued, with a fair value of $369 per share, due to its focus on specialty pharmaceuticals and international operations.
Cencora Adds Ryder Veteran to Board as Logistics Focus Grows
Cencora, Inc. has appointed Robert E. Sanchez, former CEO of Ryder System, Inc., as an independent director to its board. Sanchez brings extensive experience in logistics, supply chain, and finance, which will be valuable as Cencora strengthens its pharmaceutical distribution strategy. His background as a public-company CEO and his expertise in transportation and supply-chain operations are expected to complement the board's existing skills.
Cencora stock heads into November 4 earnings after guidance raise
Cencora (COR) is approaching its Q4 fiscal year earnings report on November 4, 2026, after raising its full-year outlook. The company's fiscal Q3 adjusted EPS of $4.48 surpassed consensus, and revenue increased by 5% year over year. Analysts maintain a "Moderate Buy" consensus with a price target significantly above the current stock price, despite the stock trading below its 50-day moving average.
ABC4571978 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Cencora, Inc. (ABC4571978) corporate bond, highlighting its key facts, coupon payment structure, and redemption information. It outlines the issuer's type, issue and maturity dates, face value, and minimum denomination, along with a brief description of Cencora, Inc.'s business operations. The bond has a 4.3% fixed semi-annual coupon, with a detailed upcoming payout schedule provided.
Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
Cencora, Inc. (NYSE: COR) announced that it will release its Fourth Quarter Fiscal 2026 results on Wednesday, November 4, 2026, before the New York Stock Exchange opens. The company will host a conference call at 8:30 a.m. ET on the same day to discuss the results, featuring President & CEO Robert P. Mauch and Executive Vice President & CFO Eva C. Boratto. The live webcast and replay will be available on Cencora's investor relations website.
AbbVie vs. Bristol Myers Squibb: A Clash Between Growth Premium and Value Trap
This article compares AbbVie (ABBV) and Bristol Myers Squibb (BMY), highlighting the dilemma investors face between AbbVie's growth premium and Bristol Myers' perceived value trap. AbbVie shows strong revenue growth driven by immunology but has a high valuation, while Bristol Myers Squibb, despite a lower valuation, faces legal challenges and patent expiry risks. The article examines their financial profiles, risks, and outlooks for 2026, suggesting AbbVie is a better long-term investment even at a premium.
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
This article compares AbbVie (ABBV) and Bristol Myers Squibb (BMY) as investment options for 2026, highlighting their financial profiles, growth drivers, and risk factors. AbbVie is seen as a higher-growth stock with new immunology drugs, while Bristol Myers Squibb offers a significant valuation discount but faces litigation and patent expiration challenges. The author recommends AbbVie for long-term investors despite its higher price, anticipating strong growth in net income.
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?
This article compares Johnson & Johnson (JNJ) and Eli Lilly (LLY) as investment options for 2026, highlighting their different approaches to the pharmaceutical market. JNJ offers diversified stability through drugs and medical devices, while LLY provides rapid growth driven by blockbuster treatments for diabetes and obesity. The analysis delves into each company's financial performance, risk profiles, and valuation metrics, concluding that Eli Lilly's high growth potential, despite its premium valuation, makes it a more compelling choice for long-term investors.
Cencora Inc (COR) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 80/100
Cencora Inc (COR) shares recently rose 3.2% to $309.78, yet GuruFocus assesses the stock as overvalued by 1.7% based on its GF Value of $304.71. Despite a strong GF Score of 80/100, indicating good overall financial health, insider selling activity totaling $14.7 million net over the past year suggests caution. Investors are advised to be wary due to the stock's overvaluation and mixed signals from guru and insider transactions.
A revocable trust holds 197 Cencora (COR) shares for director Robert E. Sanchez.
Cencora, Inc. (COR) director Robert E. Sanchez reported holding 197 shares of common stock indirectly through a revocable trust as of October 1, 2026. This information was disclosed in a Form 3 filing with the SEC. Sanchez disclaims beneficial ownership of these shares except for his pecuniary interest in them.
Is Cardinal Health (CAH) Cheap As Its CVS Deal Extension Locks In Revenue Visibility?
Cardinal Health recently extended its distribution agreement with CVS Health through June 2032, securing long-term revenue visibility. Despite this, its share price has seen a recent pullback, leading some analysts to consider it 18% undervalued with a fair value estimate near $270.94. The company's valuation is seen as mixed, with a P/E ratio higher than the industry average but potentially justified by a shift towards higher-margin services.
How Investors May Respond To McKesson (MCK) Raised 2027 EPS Guidance
McKesson (MCK) recently increased its fiscal 2027 adjusted EPS guidance, driven by strong performance in its Oncology & Multispecialty and Prescription Technology Solutions segments. This update suggests that the company's focus on specialty distribution, oncology services, and technology-enabled platforms is effectively offsetting margin pressures in its traditional drug distribution business. Analysts are now factoring in higher earnings power from these areas, projecting revenue growth of 6.9% annually and an increase in profit margins, along with significant share buybacks contributing to a higher EPS by 2029.
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
This article compares Bristol Myers Squibb and Eli Lilly and Co. as healthcare stock investments for 2026, highlighting their differing investment profiles. Bristol Myers Squibb is presented as a deep-value dividend payer with an established but maturing portfolio, facing patent expirations and regulatory pressures. Eli Lilly is depicted as a high-growth pharmaceutical company driven by breakthroughs in metabolic treatments like GLP-1 drugs, with strong revenue growth and a more conservative debt profile. The author ultimately recommends Eli Lilly due to its significant growth potential and innovative pipeline.
Cencora stock after-hours at EUR 54.63: plus 0.11 percent versus prior close
Cencora stock closed after-hours at EUR 54.63, a 0.11 percent increase from its prior close at Lang & Schwarz. The company also announced the appointment of Robert E. Sanchez to its board, effective October 1, 2026, and the launch of a new Cell and Gene Therapy Enablement service by its Accelerate Pharmacy Solutions unit.
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
This article compares Bristol Myers Squibb (BMY) and Eli Lilly (LLY), two major healthcare stocks, to determine which is a better investment in 2026. BMY is presented as a deep-value dividend payer with a maturing drug portfolio and strong free cash flow, while LLY is characterized as a high-growth pharmaceutical juggernaut driven by its metabolic and weight-loss treatments. The analysis concludes that despite BMY's lower valuation, LLY's explosive growth potential from its GLP-1 drugs makes it the more attractive buy.
Cencora elects Ryder executive Sanchez to board of directors
Cencora Inc., a pharmaceutical distribution company, has elected Robert Sanchez, former Executive Chair of Ryder System Inc., to its board of directors. Sanchez's extensive experience in logistics, supply chains, and as a public-company CEO is expected to support Cencora's strategic growth. His appointment reflects the company's commitment to leadership that can further its ambitions and provide valuable insight across operations, finance, and technology.
$100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today
Cencora (NYSE: COR) has outperformed the market over the past five years, generating an average annual return of 20.45%. An initial investment of $100 in Cencora five years ago would now be worth $254.34. The article highlights the significant impact of compounded returns on wealth growth over time.
Cencora stock last trades at USD 305.26 on September 28, 2026
Cencora shares last traded at USD 305.26 on September 28, 2026, on the New York Stock Exchange, down 0.54% from the previous close. The company also announced the election of Robert E. Sanchez as an independent director, effective October 1, increasing the board to 11 members. Sanchez, executive chair of Ryder System, will receive standard nonemployee director compensation.
Cencora Inc Lobbyists, 2014
This OpenSecrets.org page details the lobbyists employed by Cencora Inc (formerly AmerisourceBergen Corp) in 2014. It lists 29 named lobbyists, with 26 (89.7%) identified as having previously worked in the federal government, including 2 former members of Congress. The data also specifies the firms these lobbyists worked for and provides links to their individual filings.
Cencora Elects Ryder Systems' Robert Sanchez to Board
Cencora (COR) has appointed Robert Sanchez, from Ryder Systems, as a new independent director to its board, effective October 1. This strategic election aims to bring Sanchez's expertise to Cencora's leadership.
ABC5156681 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Cencora, Inc. bond (ABC5156681), highlighting key facts such as its issuer, issue and maturity dates, face value, and minimum denomination. It also details the bond's interest payment schedule, including a 2.70% semi-annual fixed rate coupon, and lists upcoming payout dates. Additionally, the profile includes information on bond redemption, noting an outstanding amount of $1.00 billion USD.
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors looking at 2026. AbbVie is transitioning its focus to newer immunology drugs, while Pfizer is pursuing aggressive acquisitions in oncology and metabolic assets to counter post-pandemic revenue declines and upcoming patent expirations. While both offer significant dividends, Pfizer appears to be the more undervalued stock based on current valuation metrics, despite AbbVie's promising pipeline.
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors in 2026, analyzing their financial performance, product pipelines, and risk profiles. While AbbVie is transitioning from its Humira era with new immunology leaders, Pfizer is focusing on oncology and metabolic assets through acquisitions, navigating post-pandemic changes and patent expirations. The author ultimately suggests Pfizer is currently undervalued despite AbbVie's promising pipeline, due to Pfizer's lower valuation metrics and recent growth in its oncology business.
A former Ryder CEO joins Cencora's board Oct. 1
Cencora, Inc. (NYSE: COR) announced the election of Robert E. Sanchez, former CEO of Ryder System, Inc., as an independent director to its Board, effective October 1, 2026. Sanchez's extensive experience in logistics, supply chains, operations, finance, and technology is expected to enhance Cencora's pharmaceutical-centric strategy and support its growth ambitions. He currently serves on the board of Texas Instruments and as a Trustee of the University of Miami.
Form 8K Cencora Inc For: 25 September By Investing.com
This article reports on Cencora Inc.'s Form 8K filing for September 25. The content is very brief, serving primarily as a notification of the SEC filing. It also includes market data for various indices, commodities, and stocks.
Cencora Elects Former Ryder CEO Robert Sanchez to Board
Cencora Inc. (NYSE: COR) has appointed Robert E. Sanchez, former CEO of Ryder System, as an independent director, effective October 1, 2026. Sanchez brings extensive experience in logistics, supply chain, operations, and finance, which is highly relevant to Cencora's pharmaceutical distribution business. His background will provide valuable insight as Cencora continues to manage its global operations and pharmaceutical-centric strategy.
Cencora, Inc. Announces Appointment of Robert E. Sanchez as Independent Director, Effective October 1, 2026
Cencora, Inc. has announced the appointment of Robert E. Sanchez to its Board of Directors as an independent director, effective October 1, 2026. Sanchez previously served as Executive Chair, and prior to that, as Chair and Chief Executive Officer of Ryder System, Inc. He brings two decades of experience with Ryder and currently serves on the Board of Directors of Texas Instruments.
Form 8K Cencora Inc For: 25 September By Investing.com
This article reports on Cencora Inc.'s Form 8K filing for September 25th, as published by Investing.com. It indicates that the company's stock symbol is COR and its price performance at the time of publication was -0.95%. The content is primarily a brief announcement with financial market data.
Form 8K Cencora Inc For: 25 September
This article from Investing.com reports on Cencora Inc.'s Form 8K filing for September 25. The content indicates it's a standard notification of a corporate event, without providing specific details about the 8K filing itself. It briefly mentions the company's stock symbol COR and its daily performance.
Cencora appoints former Ryder CEO to board of directors
Cencora, Inc. (NYSE:COR) has announced the appointment of Robert E. Sanchez, former Chair and CEO of Ryder System, Inc., as an independent director to its Board, effective October 1, 2026. Sanchez's extensive experience in logistics, supply chains, operations, finance, and technology is expected to greatly benefit Cencora's pharmaceutical-centric strategy. He previously held various leadership roles at Ryder and currently serves on the Board of Texas Instruments.
Robert E. Sanchez appointed to Cencora board effective Oct 1, 2026
Cencora (COR) has announced the appointment of Robert E. Sanchez to its Board of Directors, effective October 1, 2026. This appointment increases the board size from ten to eleven members. Sanchez will receive the same benefits and compensation as other non-employee directors, with his annual equity award prorated to the 2027 Annual Meeting, and is not yet named to any committees.
Cencora stock heads into the open after closing flat
Cencora stock closed flat at USD 312.28 on September 24, 2026, on the NYSE, while the S&P 500 slipped slightly. The article details Cencora's stock performance for the prior day, including trading range and volume. It also mentions upcoming US economic data scheduled for September 25, 2026.
Cencora (COR) Conference Updates Keep Undervalued Case In Focus
Cencora (COR) recently attended healthcare conferences, highlighting its focus on specialty pharmaceuticals, medical specialty organizations, and capital allocation. Despite a recent stock pullback, the company is viewed as 15% undervalued with a fair value of $369 per share, driven by expectations of growth in high-margin services. However, potential risks like biosimilar pricing or shifts in volume from partners could impact its performance.
Cencora stock holds near USD 316 after strong quarterly results
Cencora (COR) stock closed at USD 316.49 on September 22, 2026, up 2.50% after reporting strong Q3 fiscal 2026 results with revenues of USD 84.75 billion and earnings of USD 763.52 million. Analysts have a one-year target estimate of USD 369.31 for the stock, with an average recommendation of "Strong Buy." The next earnings date for Cencora is November 4, 2026.
Cencora stock trades at USD 314.64 below its yearly high
Cencora Inc. (NYSE: COR) is trading at USD 314.64, a 0.58% decrease from its previous close, with a market capitalization of USD 58.92 billion. The stock is currently USD 62.90 below its 52-week high of USD 377.54 and USD 69.82 above its 52-week low of USD 244.82, placing it in the upper half of its annual trading range. Cencora's price-to-earnings ratio stands at 23.01.
Cencora stock holds at USD 308.78 as specialty growth supports outlook
Cencora Inc. stock closed at USD 308.78 on September 18, 2026, remaining unchanged from its previous close, with after-hours trading showing a slight dip to USD 308.76. The company's specialty-focused strategy and fiscal 2027 outlook are highlighted as key factors influencing its market position. The article emphasizes that the September 18 closing price is the official reference, despite minor after-hours fluctuations.
Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027
Cencora executives anticipate that their specialty-focused strategy will drive continued growth through fiscal 2027, particularly in oncology and retina. The company plans to expand its capabilities in these areas, refine its portfolio, and leverage acquisitions like OneOncology to enhance its physician-services model and international operations. Cencora also addressed investor concerns regarding prescription utilization trends and its relationship with Walgreens, reaffirming its capital allocation priorities and commitment to growth-focused investments.
Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027
Cencora anticipates sustained growth through fiscal 2027, driven by its focus on specialty pharmaceuticals, particularly in oncology and retina. The company plans to leverage its expanded physician-services capabilities, contributions from OneOncology, and international business momentum. Despite a limited volume shift with Walgreens, Cencora expects accelerating fourth-quarter growth and will continue strategic investments and share repurchases.
Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch?
Cencora (COR) reported strong fiscal third-quarter results, with revenue up 5.1% and adjusted EPS climbing 12.0%, leading to raised full-year guidance and $1 billion in stock repurchases. However, this profit growth significantly outpaced sales growth, driven by the OneOncology acquisition which also introduced higher operating expenses and debt. The article highlights a key tension: while profit margins improved due to the acquisition, the long-term sustainability is questioned by increased costs, interest expenses, and the rising volume of lower-margin GLP-1 drugs.
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
This article compares AbbVie (NYSE:ABBV) and Bristol Myers Squibb (NYSE:BMY) as potential healthcare stock investments for 2026, weighing their financial performance, growth strategies, and risk profiles. While Bristol Myers Squibb appears cheaper based on valuation metrics, AbbVie is recommended due to its successful navigation of patent cliffs and strong immunology and neuroscience pipeline, making it a more predictable choice for patient investors.
Cencora (NYSE: COR) director sells $411K in shares
Cencora, Inc. director Lon R. Greenberg sold 1,280 shares of common stock on September 16, 2026, for approximately $411,264 at a price of $321.30 per share. Following this transaction, Greenberg directly holds 17,128 shares of Cencora common stock. The sale was an open-market transaction and not executed under a Rule 10b5-1 trading plan.
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
This article compares Amgen and Vertex Pharmaceuticals to determine which healthcare stock is a better investment in 2026. While Amgen offers stability and a diversified portfolio, Vertex Pharmaceuticals is highlighted for its high-growth potential, dominant position in cystic fibrosis, expanding pipeline, and superior operating margins. The author ultimately recommends Vertex for long-term investors seeking growth in the healthcare sector.
Cencora (NYSE: COR) director files notice for potential stock sale via Merrill Lynch
Cencora (COR) director Lon R. Greenberg filed a Rule 144 notice to sell 843 shares from 2026 director compensation and 437 shares from 2025 director compensation through Merrill Lynch. The filing indicates a neutral impact and sentiment, outlining the details of the proposed sale of common stock. The notice was signed on September 16, 2026.
Does Raised EPS Guidance Change The Bull Case For McKesson Stock (MCK)?
McKesson (MCK) recently increased its full-year EPS guidance, expecting 13-15% growth, and announced plans to rebrand its Medical-Surgical unit as Wellverse with a potential IPO in late 2027. The company is also acquiring Precision Medicine Group to enhance its oncology and biopharma services. While these developments signal operational strength and strategic expansion, the core investment narrative, including risks like drug pricing pressure and high leverage, remains largely unchanged.
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
This article compares Amgen and CRISPR Therapeutics to determine which healthcare stock presents a better investment opportunity in 2026. Amgen is presented as a stable, established pharmaceutical giant with a diverse portfolio, consistent revenue growth, and a dividend. CRISPR Therapeutics, while innovative with its gene-editing therapies like CASGEVY, is still in its early commercial stages, experiencing significant losses, and carries higher risk and uncertainty.
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
This article compares Amgen and Moderna, analyzing which healthcare stock presents a better investment opportunity in 2026. Amgen, an established pharmaceutical company, is favored due to its stable growth, profitability, and dividend, despite facing competition from biosimilars. Moderna, while an innovative biotech focusing on mRNA technology, carries higher risk due to substantial losses, reliance on clinical trial outcomes, and declining revenue from pandemic-related products.
Cencora (COR) Stock Forecast and Price Target 2026 $COR
Cencora (COR) currently holds a "Moderate Buy" consensus rating from 16 Wall Street analysts, with an average 12-month price target of $370.85, indicating a 15.41% potential upside from its current price of $321.34. Recent positive indicators include raised EPS outlook for fiscal 2026, strong Q2 results, and a $2.00 billion share buyback program. However, concerns exist due to a high debt-to-equity ratio of 3.53, a current ratio of 0.93, notable insider selling, and fluctuating short interest.
Cencora Inc. stock underperforms Tuesday when compared to competitors
Cencora Inc. (COR) shares dropped 1.89% on Tuesday, closing at $324.69. This underperformance occurred during a negative trading session where the S&P 500 Index fell 0.58% and the Dow Jones Industrial Average fell 1.18%. The decline marked the stock's second consecutive day of losses.
Oak Ridge Investments LLC Decreases Position in Amazon.com, Inc. $AMZN
Oak Ridge Investments LLC significantly reduced its stake in Amazon.com, Inc. (NASDAQ:AMZN) by 70.6% in the second quarter, selling 246,679 shares and retaining 102,773 shares valued at approximately $24.5 million. Despite this, institutional investors still own 72.2% of AMZN, and analysts maintain a "Moderate Buy" consensus with a $323.26 price target, driven by strong quarterly results and growth opportunities in AI and AWS. However, the company faces risks from heavy infrastructure spending, regulatory scrutiny, and recent insider sales.
